<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478205</url>
  </required_header>
  <id_info>
    <org_study_id>E2020-G000-326</org_study_id>
    <secondary_id>2006-004888-54</secondary_id>
    <nct_id>NCT00478205</nct_id>
  </id_info>
  <brief_title>Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease</brief_title>
  <official_title>Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the
      currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with
      moderate to severe Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a double-blind, double-dummy, parallel-group comparison of 23 mg
      donepezil SR with the currently marketed donepezil formulation (10 mg donepezil IR) in
      patients with moderate to severe Alzheimer's disease. Patients must have been taking 10 mg IR
      (or a bioequivalent generic) for at least 3 months prior to Screening. The study will consist
      of 24 weeks of daily administration of study medication, with clinic visits at Screening,
      Baseline, 3 weeks (safety only), 6 weeks, 12 weeks, 18 weeks and 24 weeks or early
      termination. Patients will receive either 10 mg donepezil IR in combination with the placebo
      corresponding to 23 mg donepezil SR, or 23 mg donepezil SR in combination with the placebo
      corresponding to 10 mg donepezil IR.

      A total of approximately 1600 patients will be enrolled to obtain complete data from
      approximately 1200 completed patients (Revised per Amendment 02). During the Baseline visit,
      patients will be randomized in a 2:1 ratio (23 mg donepezil SR to 10 mg donepezil IR). The
      study will be performed at approximately 200 global sites (Asia, Oceania, Europe, India,
      Israel, North America, South Africa, and South America) (Revised per Amendments 01 and 02).
      An Independent Data Monitoring Committee (IDMC) will be established to review safety aspects
      of the study and to evaluate the results of a planned interim analysis.

      Patients who complete the study may be eligible to undergo evaluation for enrollment into the
      open-label extension study, E2020-G000-328.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 24 in SIB Total Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Change From Baseline in Modified CIBIC+ to Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in ADCS-ADL Total Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in MMSE Total Score</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1467</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aricept (donepezil SR 23 mg)</intervention_name>
    <description>Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:
23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Donepezil hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aricept (donepezil IR 10 mg)</intervention_name>
    <description>Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:
10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Donepezil hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Patients:

          1. Written informed consent.

          2. Patient Age range: Adult patients, 45 to 90 years of age, inclusive.

          3. The caregiver must separately meet the specified inclusion/exclusion criteria for
             caregivers.

          4. Women must be of non-child-bearing potential (&gt;1 year post-menopausal or surgically
             sterile).

          5. There must be diagnostic evidence of probable Alzheimer's disease (AD).

          6. The patient must have been receiving Aricept at a dose of dose of 10 mg IR (or 10 mg
             dose of generic donepezil bioequivalent to Aricept), for at least 3 months prior to
             the Screening visit.

          7. A cranial image is required, with no evidence of focal brain disease that would
             account for dementia.

          8. The patient must meet certain psychometric test criteria related to the degree of
             impairment of cognitive functioning.

          9. Health: physically healthy and ambulatory or ambulatory-aided (i.e., walker or cane);
             corrected vision and hearing sufficient for compliance with testing procedures, and
             able to read prior to disease onset.

         10. Clinical laboratory values must be within normal limits or, if abnormal, must be
             judged not clinically significant by the investigator.

         11. Specified doses of selective serotonin reuptake inhibitors (SSRIs) are allowed in the
             study if dosage is within approved dose range and stable for 3 months prior to
             Screening.

         12. Other medical conditions, such as hypertension and cardiac disease must be
             well-controlled and the patient maintained on stable doses of medications for 3
             months.

         13. Patients with diabetes mellitus or risk factors for diabetes mellitus may be enrolled
             in the study provided that the patient's disease is stable and that there have been no
             recent hospitalizations for diabetes complications.

         14. Patients whose serum B12 levels at Screening are below the normal range may
             nonetheless be admitted to the study if they subsequently show normal levels prior to
             Baseline.

         15. Patients with hypothyroidism who are on a stable dose of medication for at least 12
             weeks prior to Screening, have normal TSH and free T4 at Screening, and are considered
             euthyroid will be eligible.

         16. Concomitant Medications: Under specified circumstances, the following medications may
             be allowed: chronic daily benzodiazepine use, bronchodilator medications for treatment
             of chronic obstructive pulmonary disease (COPD), and memantine. Certain other
             additional prescription treatments for AD, such as other cholinesterase inhibitors,
             must have been discontinued for at least 3 months prior to screening.

         17. The patient must have a relative/caregiver who supervises the regular taking of the
             drug at the correct dose and is alert for possible side effects, unless the patient's
             legal guardian takes on this task.

        Inclusion Criteria for Caregivers:

        The designated caregiver must be sufficiently familiar with the patient (as determined by
        the investigator) to provide accurate data. The caregiver must have regular contact with
        the patient (i.e., an average of 10 or more hours per week), must be able to observe for
        possible adverse events, and must be able to accompany the patient to all visits.

        Exclusion Criteria for Patients:

          1. Patients are excluded if they are taking (a) no medication for Alzheimer's disease,
             (b) Aricept or bioequivalent generic donepezil at doses other than 10 mg daily, or 10
             mg for less than 3 months before Screening; (c) other medications for Alzheimer's
             disease, except that memantine, Vitamin E, fish oil, and/or gingko biloba are allowed
             if doses have been stable for at least 3 months prior to the Screening visit. Patients
             undergoing any alternative medical techniques, such as acupuncture or acupressure,
             specifically for the treatment of AD are not eligible

          2. No caregiver available to meet the inclusion criteria for caregivers.

          3. Patients who have no measurable blood levels of donepezil in blood samples collected
             at Screening.

          4. Patients with neurological disorders that affect cognition or the ability to assess
             cognition but are distinguishable from Alzheimer's disease. These include, but are not
             limited to, Parkinson's disease, multi-infarct dementia, and dementia due to
             cerebrovascular disease.

          5. Patients with psychiatric disorders affecting the ability to assess cognition such as
             schizophrenia, bipolar or unipolar depression. Patients with clinically significant
             sleep disorders will also be excluded unless these are controlled by treatment and
             clinically stable for &gt; 3 months prior to screening.

          6. Patients with dementia complicated by other organic disease or Alzheimer's disease
             with delirium.

          7. Patients with drug or alcohol abuse or dependence within the past 5 years according to
             DSM IV criteria.

          8. Patients with any conditions affecting absorption, distribution, or metabolism of the
             study medication (e.g., inflammatory bowel disease, gastric or duodenal ulcers,
             hepatic disease, or severe lactose intolerance).

          9. Patients with evidence of clinically significant, active gastrointestinal, renal,
             hepatic, respiratory, endocrine, or cardiovascular system disease (including history
             of life-threatening arrhythmias).

         10. Patients with a history of cancer (does not include basal or squamous cell carcinoma
             of the skin) treated within 5 years prior to study entry, or current evidence of
             malignant neoplasm, recurrent, metastatic disease. Males with localized prostate
             cancer requiring no treatment would not be excluded.

         11. Known plan for elective surgery during the treatment period that would require general
             anesthesia and administration of neuromuscular blocking agents.

         12. Donation of blood or blood products during 30 days prior to Screening or plans to
             donate blood while participating in the study or within 30 days after completion of
             the study.

         13. Patients who are unwilling or unable to fulfill the requirements of the study.

         14. Known hypersensitivity to acetylcholinesterase inhibitors or memantine.

         15. Use of any prohibited prior or concomitant medications) Any condition that would make
             the patient, in the opinion of the investigator, unsuitable for the study.

         16. Involvement in any other investigational drug clinical trial during the preceding 3
             months, or likely involvement in any other such trial during the course of this study.

         17. Patients taking concomitant antidepressant medication known to have significant
             anticholinergic effects, such as tricyclic antidepressants prescribed at doses
             recommended for the treatment of major depression.

         18. Patients who cannot swallow or who have difficult swallowing whole tablets.

         19. Patients with fecal and/or urinary incontinence who are unable to cooperate with
             routine specimen collection.

        Exclusion Criteria for Caregivers:

          1. Caregivers who are unwilling or unable to give informed consent or otherwise to
             fulfill the requirements of the study.

          2. Caregivers who do not meet certain psychometric test criteria.

          3. Any condition that would make the caregiver, in the opinion of the Investigator,
             unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Yardley, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limted</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MedTrials, Inc.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>November 12, 2012</results_first_submitted>
  <results_first_submitted_qc>January 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2013</results_first_posted>
  <disposition_first_submitted>February 17, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 25, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 27, 2010</disposition_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to Severe Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Donepezil SR 23 mg</title>
          <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Donepezil IR 10 mg</title>
          <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="981"/>
                <participants group_id="P2" count="486"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="685"/>
                <participants group_id="P2" count="399"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Request of Investigator or Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donepezil SR 23 mg</title>
          <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Donepezil IR 10 mg</title>
          <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="963"/>
            <count group_id="B2" value="471"/>
            <count group_id="B3" value="1434"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Safety Population</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.9" spread="8.53"/>
                    <measurement group_id="B2" value="73.8" spread="8.56"/>
                    <measurement group_id="B3" value="73.8" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Safety Population: All patients randomized who took at least one dose of study medication and who had at least one postbaseline safety assessment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="607" spread="63.0"/>
                    <measurement group_id="B2" value="294" spread="62.4"/>
                    <measurement group_id="B3" value="901" spread="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="356" spread="37.0"/>
                    <measurement group_id="B2" value="177" spread="37.6"/>
                    <measurement group_id="B3" value="533" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race (Safety Population)</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="708"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="1054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 24 in SIB Total Score</title>
        <description>The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Intent-to-treat (ITT) population: All Randomized patients in Safety Population and Severe Impairment Battery (SIB) or Clinician Interview-Based Impression of Severity Plus Caregiver Input (CIBIS+) data available at Baseline and SIB or Clinician Interview-Based Impression of Change Plus caregiver Input (CIBIC+ ) data available post-Baseline; LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg</title>
            <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Donepezil IR 10 mg</title>
            <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in SIB Total Score</title>
          <description>The SIB is an assessment of cognitive dysfunction across nine domains such as memory, language, and orientation. The score ranges from 0 (worst) to 100 (best). This outcome was calculated using the LOCF (last observation carried forward) method.</description>
          <population>Intent-to-treat (ITT) population: All Randomized patients in Safety Population and Severe Impairment Battery (SIB) or Clinician Interview-Based Impression of Severity Plus Caregiver Input (CIBIS+) data available at Baseline and SIB or Clinician Interview-Based Impression of Change Plus caregiver Input (CIBIC+ ) data available post-Baseline; LOCF</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.58"/>
                    <measurement group_id="O2" value="0.4" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in ADCS-ADL Total Score</title>
        <description>The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg</title>
            <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Donepezil IR 10 mg</title>
            <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in ADCS-ADL Total Score</title>
          <description>The ADCS-ADL (Alzhemier's Disease Cooperative Study-Activities of Daily Living) is a 19-item assessment scale used to measure a patient's basic functional abilities, such as walking, grooming, and bathing.Scores range from 0 to 54, with a higher score indicating greater functional ability.</description>
          <population>ITT population, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="6.83"/>
                    <measurement group_id="O2" value="-1.2" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in MMSE Total Score</title>
        <description>The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg</title>
            <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Donepezil IR 10 mg</title>
            <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in MMSE Total Score</title>
          <description>The MMSE (Mini-Mental State Examination) is a 30-item test that evaluates 5 domains of cognitive function (orientation to time and place, immediate and delayed recall, attention, calculation, and language). The scores range from 0 (most impaired) to 30 (no impaiment).</description>
          <population>ITT population, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.93"/>
                    <measurement group_id="O2" value="0.4" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Change From Baseline in Modified CIBIC+ to Week 24</title>
        <description>The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>ITT population, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Donepezil SR 23 mg</title>
            <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Donepezil IR 10 mg</title>
            <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Change From Baseline in Modified CIBIC+ to Week 24</title>
          <description>The CIBIC+ is a rating scale derived from an interview with the patient and caregiver with an independent rater designed to measure several domains of patient function, such as mental/cognitive state, behavior, and activities of daily living. The scores range from 1 (marked improvement) to 7 (marked worsening).</description>
          <population>ITT population, LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="909"/>
                <count group_id="O2" value="462"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="1.07"/>
                    <measurement group_id="O2" value="4.29" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events (AEs) were recorded from the time of informed consent until after the Final Visit or Early Termination.</time_frame>
      <desc>Serious adverse events (SAEs) were monitored through the termination visit and through 30 days after study drug discontinuation, whichever was longer.</desc>
      <group_list>
        <group group_id="E1">
          <title>Donepezil SR 23 mg</title>
          <description>Donepezil sustained release (SR) 23 mg in combination with placebo corresponding to donepezil IR 10 mg ; dosing continued for a 24-week treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Donepezil IR 10 mg</title>
          <description>Donepezil immediate release (IR) 10 mg in combination with placebo corresponding to donepezil SR 23 mg; dosing continued for a 24-week treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Behavioural and psychiatric symptoms of dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Poriomania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="233" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="471"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="963"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="471"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Inc.</name_or_title>
      <organization>Eisai Call Center</organization>
      <phone>888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

